达那唑结构式
|
常用名 | 达那唑 | 英文名 | Danazol |
---|---|---|---|---|
CAS号 | 17230-88-5 | 分子量 | 337.455 | |
密度 | 1.2±0.1 g/cm3 | 沸点 | 478.2±45.0 °C at 760 mmHg | |
分子式 | C22H27NO2 | 熔点 | 224.4-226.8ºC | |
MSDS | 中文版 美版 | 闪点 | 243.0±28.7 °C | |
符号 |
GHS07, GHS08 |
信号词 | Warning |
达那唑用途Danazol是合成类固醇Ethisterone的衍生物, 抑制促性腺激素产生, 且具有一定的弱雄激素作用。 |
中文名 | 达那唑 |
---|---|
英文名 | danazol |
中文别名 | 安宫唑 | 17ALPHA-孕甾-2,4-二烯-20-炔并[2,3-D]异唑-17BETA-醇 |
英文别名 | 更多 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 478.2±45.0 °C at 760 mmHg |
熔点 | 224.4-226.8ºC |
分子式 | C22H27NO2 |
分子量 | 337.455 |
闪点 | 243.0±28.7 °C |
精确质量 | 337.204193 |
PSA | 46.26000 |
LogP | 4.70 |
外观性状 | 白色固体 |
蒸汽压 | 0.0±1.3 mmHg at 25°C |
折射率 | 1.604 |
分子结构 | 1、 摩尔折射率:95.82 2、 摩尔体积(m3/mol):278.6 3、 等张比容(90.2K):759.0 4、 表面张力(3.0 dyne/cm):55.0 5、 极化率(0.5 10 -24cm 3):37.98 |
计算化学 | 1.疏水参数计算参考值(XlogP):3.8 2.氢键供体数量:1 3.氢键受体数量:3 4.可旋转化学键数量:1 5.互变异构体数量:无 6.拓扑分子极性表面积46.3 7.重原子数量:25 8.表面电荷:0 9.复杂度:677 10.同位素原子数量:0 11.确定原子立构中心数量:6 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 | 1. 性状:不确定 2. 密度(g/mL,25/4℃):不确定 3. 相对蒸汽密度(g/mL,空气=1):不确定 4. 熔点(ºC):224.4-226.8 5. 沸点(ºC,常压):不确定 6. 沸点(ºC, 5.2kPa):不确定 7. 折射率:不确定 8. 闪点(ºC):不确定 9. 比旋光度(º):不确定 10. 自燃点或引燃温度(ºC):不确定 11. 蒸气压(kPa,25ºC):不确定 12. 饱和蒸气压(kPa,60ºC):不确定 13. 燃烧热(KJ/mol):不确定 14. 临界温度(ºC):不确定 15. 临界压力(KPa):不确定 16. 油水(辛醇/水)分配系数的对数值:不确定 17. 爆炸上限(%,V/V):不确定 18. 爆炸下限(%,V/V):不确定 19. 溶解性:不确定 |
符号 |
GHS07, GHS08 |
---|---|
信号词 | Warning |
危害声明 | H312 + H332-H361 |
警示性声明 | P261-P280 |
个人防护装备 | Eyeshields;full-face particle respirator type N100 (US);Gloves;respirator cartridge type N100 (US);type P1 (EN143) respirator filter;type P3 (EN 143) respirator cartridges |
危害码 (欧洲) | Xn:Harmful |
风险声明 (欧洲) | R20/21/22;R63 |
安全声明 (欧洲) | S22-S36 |
危险品运输编码 | TU4157070 |
WGK德国 | 3 |
RTECS号 | TU4157070 |
海关编码 | 2937290014 |
海关编码 | 2937290014 |
---|---|
中文概述 | HS:2937290014 达那唑;脱氢氯甲基睾酮〔包括雄-1-烯-3,17-二酮;(Δ)雄烯二醇;普拉睾酮;去氧甲基睾酮〕 增值税率:17.0% 退税率:9.0% 监管条件:L 最低关税:4.0% 普通关税:30.0% |
申报要素 | 品名, 成分含量, 用途, 包装 |
监管条件 | L.药品进出口准许证 |
Summary | HS:2937290014 (3s,8r,9s,10r,13s,14s)-3-hydroxy-10,13-dimethyl-3,4,7,8,9,10,11,12,13,14,15,16-dodecahydro-1h-cyclopenta[a]phenanthren-17(2h)-one VAT:17.0% Tax rebate rate:9.0% Supervision conditions:l MFN tariff:4.0% General tariff:30.0% |
Fasted-state simulated intestinal fluid "FaSSIF-C", a cholesterol containing intestinal model medium for in vitro drug delivery development.
J. Pharm. Sci. 104 , 2213-24, (2015) A set of biorelevant media "fasted-state simulated intestinal fluid with cholesterol (FaSSIF-C)" for the in vitro study of intestinal drug dissolution in the duodenum was developed. These contain chol... |
|
Non-linear increases in danazol exposure with dose in older vs. younger beagle dogs: the potential role of differences in bile salt concentration, thermodynamic activity, and formulation digestion.
Pharm. Res. 31(6) , 1536-52, (2014) To explore the possibility that age-related changes in physiology may result in differences in drug bioavailability after oral administration of lipid based formulations of danazol.Danazol absorption ... |
|
An in vitro digestion test that reflects rat intestinal conditions to probe the importance of formulation digestion vs first pass metabolism in Danazol bioavailability from lipid based formulations.
Mol. Pharm. 11(11) , 4069-83, (2014) The impact of gastrointestinal (GI) processing and first pass metabolism on danazol oral bioavailability (BA) was evaluated after administration of self-emulsifying drug delivery systems (SEDDS) in th... |
(1R,3aS,3bR,10aR,10bS,12aS)-1-Ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d][1,2]oxazol-1-ol |
Danazolum |
danazolum [INN_la] |
Danol |
Danatrol |
Ladogal |
Winobanin |
17a-Pregn-4-en-20-yno[2,3-d]isoxazol-17-ol |
MFCD00056838 |
(1R,3aS,3bR,10aR,10bS,12aS)-1-ethynyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol |
Chronogyn |
Danocrine |
(1R,3aS,3bR,10aR,10bS,12aS)-1-éthynyl-10a,12a-diméthyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodécahydro-1H-cyclopenta[7,8]phénanthro[3,2-d]isoxazol-1-ol |
Cyclomen |
Danzol |
EINECS 241-270-1 |
(1R,3aS,3bR,10aR,10bS,12aS)-1-Ethinyl-10a,12a-dimethyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-1H-cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol |
(17a)-Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol |
17a-Ethynyl-17b-hydroxy-4-androsteno[2,3-d]isoxazole |
1H-Cyclopenta[7,8]phenanthro[3,2-d]isoxazol-1-ol, 1-ethynyl-2,3,3a,3b,4,5,10,10a,10b,11,12,12a-dodecahydro-10a,12a-dimethyl-, (1R,3aS,3bR,10aR,10bS,12aS)- |